Vogenx shares more than double after $81M biotech IPO
What's the deal? VogenxDealroom has a profile for this one. Try Dealroom →, a US development-stage biopharmaceutical company, raised $81.25 million in its August 12 IPO on the Nasdaq under the ticker VOGX. It sold 6,250,000 shares at $13.00 each.
Why now? The company's quiet period ends Monday, September 21, freeing underwriters to launch research coverage. That restriction, mandated by the Securities and Exchange Commission, bars insiders and underwriters from issuing reports in the weeks after a listing.
What's the endgame? Vogenx focuses on small-molecule therapies for inflammatory and metabolic diseases. Its lead candidate, VGX-1027, is an orally administered compound studied for anti-inflammatory and immunomodulatory effects in conditions including diabetes.
By the numbers: Shares opened at $32.21 on Wednesday, well above the $13.00 offer price, ranging from a 52-week low of $12.95 to a high of $35.50. Early analyst coverage has been bullish: JonesTrading set a "buy" rating with a $55.00 target, and WBB SecuritiesDealroom has a profile for this one. Try Dealroom → issued a "speculative buy" at $42.00.
The consensus rating is "Strong Buy," with an average price target of $48.50, according to MarketBeat.comDealroom has a profile for this one. Try Dealroom →.
What could go wrong? Vogenx remains development-stage, with no widely marketed commercial products. VGX-1027 is still investigational, leaving the company's valuation tied to clinical progress rather than revenue.
The signal: The end of the quiet period typically brings a wave of underwriter research that can move a newly listed stock. For Vogenx, already trading at more than double its IPO price, that coverage will test whether early enthusiasm holds.
Read more: zolmax.com
Image credit: thetaxhaven
